Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

AVIFAVIR, 2020
 
NCT04434248
RCTfavipiravir standard of careCOVID 19 hospitalized, COVID-19 mild to moderatesome concern
20/20 suggested
  • suggested 2.9-fold increase in PCR-negative conversion,PCR-negative conversion (7-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
Adverse drug reactions to AVIFAVIR were reported in 7/40 (17.5%) patients, including diarrhea, nausea, vomiting, chest pain and an increase in liver transaminase levels. The adverse drug reactions were mild to moderate and caused early discontinuation of the study drug in 2/40 (5.0%) patients.

COVID 19 all comers meta-analysis

Chang Chen et al., 2020
 
ChiCTR2000030254
RCTfavipiravir umifenovir (arbidol)COVID 19 all comerssome concern
120/120 inconclusive
    jRCTs041190120, 2020
     
    jRCTs041190120
    RCTfavipiravir favipiravir COVID 19 all comershigh
    44/45 inconclusive
    • inconclusive 42 % increase in PCR-negative conversion,PCR-negative conversion (time to event analysis only) (PE) but with a low degree of certainty due to high risk of bias
    Lou Y - FAVIPIRAVIR, 2020
     
    ChiCTR2000029544
    RCTfavipiravir standard of careCOVID 19 all comerssome concern
    10/10 inconclusive
    • inconclusive 82 % decrease in PCR-negative conversion,PCR-negative conversion (14-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
    NCT04310228-FAVI (Zhao), 2020
     
    ChiCTR2000030894
    RCTfavipiravir tocilizumab COVID 19 all comerssome concern
    -/- inconclusive
    • inconclusive 68 % decrease in clinical improvement,clinical improvement (14-day),clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
    Calik, 2020 OBSfavipiravir hydroxychloroquineCOVID 19 all comerscritical
    -/- no results
      Cai -FAVIPIRAVIR, 2020
       
      ChiCTR2000029600
      NRafavipiravir interferonCOVID 19 all comersNA
      35/45 suggested
      • suggested 5.5-fold increase in clinical improvement,clinical improvement (14-day)
      Cai -FAVIPIRAVIR, 2020
       
      ChiCTR2000029600
      NRafavipiravir lopinavir/ritonavirCOVID 19 all comersNA
      35/45 suggested
      • suggested 5.5-fold increase in clinical improvement,clinical improvement (14-day)

      COVID-19 mild to moderate meta-analysis

      Dabbous HM, 2020
       
      NCT04349241
      RCTfavipiravir standard of careCOVID-19 mild to moderatesome concern
      50/50 inconclusive
        Khamis, 2020 RCTfavipiravir standard of careCOVID-19 mild to moderatesome concern
        44/45 inconclusive
          NCT04542694, 2020
           
          NCT04542694
          RCTfavipiravir standard of careCOVID-19 mild to moderatesome concern
          100/100 suggested
          • suggested 12.0-fold increase in PCR-negative conversion with a moderate degree of certainty due to some concern in risk of bias
          Ruzhentsova T, 2020
           
          NCT04501783
          RCTfavipiravir standard of careCOVID-19 mild to moderatesome concern
          112/56 suggested
          • suggested 63 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
          • inconclusive 28 % increase in PCR-negative conversion,PCR-negative conversion (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
          • suggested 28 % increase in clinical improvement (14-day) with a moderate degree of certainty due to some concern in risk of bias
          • suggested 50 % increase in clinical improvement (7-day) with a moderate degree of certainty due to some concern in risk of bias
          Udwadia ZF, 2020
           
          CTRI/2020/05/025114
          RCTfavipiravir standard of careCOVID 19 hospitalized, COVID-19 mild to moderatesome concern
          75/75 safety concern
          • inconclusive 37 % increase in PCR-negative conversion,PCR-negative conversion (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
          • suggested 75 % increase in clinical improvement,clinical improvement (time to event analysis only),clinical improvement (28-day) with a moderate degree of certainty due to some concern in risk of bias
          • suggested 94 % decrease in ventilation (time to event analysis only),ventilation with a moderate degree of certainty due to some concern in risk of bias
          • statistically significant 5.4-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias

          COVID-19 severe or critically meta-analysis

          Kocayigit H, 2020 OBSfavipiravir lopinavir/ritonavirCOVID-19 severe or criticallyNA
          65/42 inconclusive

            PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
            Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).